Is inhibition of phosphodiesterase type 5 by sildenafil a promising therapy for volume-overload heart failure?

Circulation

Volumn 125, Issue 11, 2012, Pages 1341-1343

  Dai, Wangde ^a   Kloner, Robert A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE V; SILDENAFIL; TADALAFIL;

ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; FLUSHING; HEADACHE; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIDE EFFECT; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; MALE; MITRAL VALVE INSUFFICIENCY; PHYSICAL CONDITIONING, ANIMAL; PHYSICAL ENDURANCE; PIPERAZINES; PURINES; SULFONES; VENTRICULAR REMODELING;

EID: 84858700164     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.094912     Document Type: Article

References (20)

1. Kloner RA. Sex and the patient with cardiovascular risk factors: focus on sildenafil. Am J Med. 2000; 109(suppl 9A): 13S-21S.
2. Schwartz BG, Levine LA, Comstock G, Stecher VJ, Kloner RA. Cardiac uses of phosphodiesterase-5 inhibitors. J Am Coll Cardiol. 2012; 59: 9-15.
3. Ockaili R, Salloum F, Hawkins J, Kukreja RC. Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol. 2002; 283: H1263-H1269.
4. Reffelmann T, Kloner RA. Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation. Cardiovasc Res. 2003; 59: 441-449. (Pubitemid 37272038)
5. Sesti C, Florio V, Johnson EG, Kloner RA. The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size. Int J Impot Res. 2007; 19: 55-61. (Pubitemid 46067349)
6. Salloum FN, Takenoshita Y, Ockaili RA, Daoud VP, Chou E, Yoshida K, Kukreja RC. Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits. J Mol Cell Cardiol. 2007; 42: 453-458. (Pubitemid 46135606)
7. Elrod JW, Greer JJ, Lefer DJ. Sildenafil-mediated acute cardioprotection is independent of the NO/cGMP pathway. Am J Physiol Heart Circ Physiol. 2007; 292: H342-H347. (Pubitemid 46105196)
8. Das A, Xi L, Kukreja RC. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis: essential role of nitric oxide signaling. J Biol Chem. 2005; 280: 12944-12955.
9. Salloum FN, Abbate A, Das A, Houser JE, Mudrick CA, Qureshi IZ, Hoke NN, Roy SK, Brown WR, Prabhakar S, Kukreja RC. Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol. 2008; 294: H1398-H1406. (Pubitemid 351468739)
10. Chau VQ, Salloum FN, Hoke NN, Abbate A, Kukreja RC. Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway. Am J Physiol Heart Circ Physiol. 2011; 300: H2272-H2279.
11. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005; 11: 214-222. (Pubitemid 40321358)
12. Hassan MA, Ketat AF. Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. BMC Pharmacol. 2005; 5: 1-7.
13. Kim KH, Kim YJ, Ohn JH, Yang J, Lee SE, Lee SW, Kim HK, Seo JW, Sohn DW. Long-term effects of sildenafil in a rat model of chronic mitral regurgitation: benefits on ventricular remodeling and exercise capacity. Circulation. 2012; 125: 1390-1401.
14. Lu Z, Xu X, Hu X, Lee S, Traverse JH, Zhu G, Fassett J, Tao Y, Zhang P, dos Remedios C, Pritzker M, Hall JL, Garry DJ, Chen Y. Oxidative stress regulates left ventricular PDE5 expression in the failing heart. Circulation. 2010; 121: 1474-1483.
15. Al-Ameri H, Kloner RA. Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors. Int J Impot Res. 2009; 21: 149-157.
16. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flowmediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol. 2000; 36: 845-851.
17. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011; 4: 8-17.
18. Lewis GD, Lachmann J, Camuso J, Lepore JJ, Shin J, Martinovic ME, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation. 2007; 115: 59-66. (Pubitemid 46058612)
19. Chapman TH, Wilde M, Sheth A, Madden BP. Sildenafil therapy in secondary pulmonary hypertension: is there benefit in prolonged use? Vascul Pharmacol. 2009; 51: 90-95.
20. Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009; 119: 2894-2903.